Page last updated: 2024-09-04

tipifarnib and Thyroid Cancer, Anaplastic

tipifarnib has been researched along with Thyroid Cancer, Anaplastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cavaco, BM; Leite, V; Lopes-Ventura, S; Marques, IJ; Matias, AT; Moura, MM; Pojo, M	1

Other Studies

1 other study(ies) available for tipifarnib and Thyroid Cancer, Anaplastic

Article	Year
The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines. Journal of endocrinological investigation, 2019, Volume: 42, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Gene Expression Regulation, Neoplastic; Humans; Mutation; Piperazines; Proto-Oncogene Proteins p21(ras); Pyridines; Quinolones; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tumor Cells, Cultured	2019

Article

Year

The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.

Journal of endocrinological investigation, 2019, Volume: 42, Issue:5

Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Gene Expression Regulation, Neoplastic; Humans; Mutation; Piperazines; Proto-Oncogene Proteins p21(ras); Pyridines; Quinolones; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tumor Cells, Cultured

2019